文献速递病毒性肝炎艾滋病与性传播感染

HCV检测与治疗对旧金山男男性行为者及注射吸毒者中HCV传播的影响:一项模型分析

Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
PubMed 文献 · J Infect Dis · 2023-01-01

研究建立MSM人群HCV/HIV动态传播模型并校准至旧金山数据,评估当前HCV检测与治疗能否在2030年实现WHO消除目标。若COVID-19相关检测/治疗下降持续至2030年,ever MSM-IDU的HCV发病率2015-2030年将下降84.9%,主要归因于检测与治疗,可实现WHO目标。

要点

  • ever MSM-IDU的HCV抗体流行率15.5%(2011年),HIV流行率32.8%(2017年)。
  • 2015年ever MSM-IDU的HCV发病率为1.2/100人年(95%CrI 0.8-1.6)。
  • 若COVID-19相关下降持续至2030年,HCV发病率2015-2030年降84.9%,可实现WHO目标。

核心结论

  • 模型估计旧金山ever MSM-IDU的HCV发病率2015-2030年将下降超过80%,达到WHO消除目标。

研究设计与样本

  • 建立MSM人群HCV/HIV动态传播模型,并校准至旧金山数据。
  • 校准数据包括ever MSM-IDU的HCV抗体流行率15.5%(2011年)和HIV流行率32.8%(2017年)。
  • MSM的HCV检测率较高(2011-2019年曾检测者79%-86%),确诊MSM的治疗率较高(2018年曾治疗者65%)。

主要发现

  • 2022年全部MSM中新发HCV感染有43%与注射吸毒相关。
  • 2015年ever MSM-IDU的HCV发病率为1.2/100人年(95%CrI 0.8-1.6)。
  • 若COVID-19相关HCV检测/治疗下降持续至2030年,ever MSM-IDU的HCV发病率2015-2030年将下降84.9%(95%CrI 72.3%-90.8%)。
  • 该下降主要归因于HCV检测与治疗(75.8%;95%CrI 66.7%-89.5%)。
  • 若COVID-19干扰在2025年或2022年恢复,HCV发病率预计下降94%-95%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men who have sex with men who ever injected drugs (ever MSM-IDU) carry a high hepatitis C virus (HCV) burden. We estimated whether current HCV testing and treatment in San Francisco can achieve the 2030 World Health Organization (WHO) HCV elimination target on HCV incidence among ever MSM-IDU. METHODS: A dynamic HCV/HIV transmission model among MSM was calibrated to San Francisco data, including HCV antibody (15.5%, 2011) and HIV prevalence (32.8%, 2017) among ever MSM-IDU. MSM had high HCV testing (79%-86% ever tested, 2011-2019) and diagnosed MSM had high HCV treatment (65% ever treated, 2018). Following coronavirus disease 2019 (COVID-19)-related lockdowns, HCV testing and treatment decreased by 59%. RESULTS: Among all MSM, 43% of incident HCV infections in 2022 were IDU-related. Among ever MSM-IDU in 2015, HCV incidence was 1.2/100 person-years (95% credibility interval [CrI], 0.8-1.6). Assuming COVID-19-related declines in HCV testing/treatment persist until 2030, HCV incidence among ever MSM-IDU will decrease by 84.9% (95% CrI, 72.3%-90.8%) over 2015-2030. This decline is largely attributed to HCV testing and treatment (75.8%; 95% CrI, 66.7%-89.5%). Slightly greater decreases in HCV incidence (94%-95%) are projected if COVID-19 disruptions recover by 2025 or 2022. CONCLUSIONS: We estimate that HCV incidence will decline by >80% over 2015-2030 among ever MSM-IDU in San Francisco, achieving the WHO target.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Artenie A, Stone J, Facente SN, et al. Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis. J Infect Dis. 2023. PMID: 37486337. doi:10.1093/infdis/jiad169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。